<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330276</url>
  </required_header>
  <id_info>
    <org_study_id>08847</org_study_id>
    <secondary_id>1R01AT008310-01</secondary_id>
    <nct_id>NCT02330276</nct_id>
  </id_info>
  <brief_title>Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin</brief_title>
  <acronym>Epicatechin</acronym>
  <official_title>(+)-Epicatechin: Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Diego Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early Phase Pre-Clinical and Initial Clinical Research on (+)- Epicatechin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a double-blinded randomized Phase I study that will include dose-ranging one
      day PK and pharmacodynamic (PD) studies. Subjects will include healthy individuals and
      subjects who meet the American Diabetes Association (ADA) criteria for pre-diabetes,
      including IFG.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites</measure>
    <time_frame>Baseline and 24 hours</time_frame>
    <description>This will be initial PK study on synthetic (+)-epicatechin in humans. Circulating and urinary concentrations of intact epicatechin and epicatechin metabolites, including specific enantiomers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Major Safety Endpoints</measure>
    <time_frame>Baseline and 24 hours</time_frame>
    <description>Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change), HR (10 bpm), creatinine (&gt;1.5 ULN), and highly conservative changes in alkaline phosphatase and liver transaminases (&gt;1.5 ULN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)</measure>
    <time_frame>Baseline and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)</measure>
    <time_frame>Baseline and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)</measure>
    <time_frame>Baseline and 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>10 mg (+)-epicatechin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg (+)-epicatechin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg (+)-epicatechin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(+)-Epicatechin</intervention_name>
    <description>The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
    <arm_group_label>10 mg (+)-epicatechin</arm_group_label>
    <arm_group_label>30 mg (+)-epicatechin</arm_group_label>
    <arm_group_label>100 mg (+)-epicatechin</arm_group_label>
    <other_name>Epicatechin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy or pre-diabetic based on medical history

          -  Male or female

          -  Must be 21 to 75 years of age (inclusive)

          -  Able to give informed consent to the procedures

          -  If female, must be either postmenopausal or test negative for pregnancy at screening
             and on the day of the procedure. Women on estrogen therapy will be included.

          -  If of childbearing potential, must practice and be willing to continue to practice
             appropriate birth control during the entire duration of the study

          -  Medication use stable for 4 weeks

          -  Body Mass Index (BMI) &gt; 27 kg/m^2

          -  Definition of pre-diabetes: impaired fasting glucose (IFG, fasting glucose = 100-125
             mg/dL) and elevated HbA1c (5.7-6.4%), each in the absence of other risk factors for
             diabetes

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Pregnancy

          -  Younger than 21 or older than 75 years of age

          -  Clinically significant abnormalities in liver or kidney function (&gt;3x ULN), determined
             in the last 6 months by a certified clinical laboratory

          -  Recent MI or stroke (within 6 months of screening)

          -  Blood pressure (BP) &gt;160 mmHg Systolic and &gt;100 mmHg Diastolic

          -  Medications - thiazolidinediones, any steroids, anti-depressants, weight loss drugs

          -  Other diseases, besides type 2 diabetes, influencing carbohydrate metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert R Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Veterans Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <results_first_submitted>January 8, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Veterans Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Robert R. Henry, MD</investigator_full_name>
    <investigator_title>Chief, Section of Diabetes, Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>10 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
        <group group_id="P2">
          <title>30 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
        <group group_id="P3">
          <title>100 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
        <group group_id="B2">
          <title>30 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
        <group group_id="B3">
          <title>100 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites</title>
        <description>This will be initial PK study on synthetic (+)-epicatechin in humans. Circulating and urinary concentrations of intact epicatechin and epicatechin metabolites, including specific enantiomers</description>
        <time_frame>Baseline and 24 hours</time_frame>
        <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O2">
            <title>30 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O3">
            <title>100 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites</title>
          <description>This will be initial PK study on synthetic (+)-epicatechin in humans. Circulating and urinary concentrations of intact epicatechin and epicatechin metabolites, including specific enantiomers</description>
          <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
          <units>nM*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metabolites (AUC nM*hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.8" spread="122.2"/>
                    <measurement group_id="O2" value="132.7" spread="148.0"/>
                    <measurement group_id="O3" value="162.3" spread="209.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epicatechin-sulfate (AUC nM*hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.3" spread="119.2"/>
                    <measurement group_id="O2" value="1639" spread="389.0"/>
                    <measurement group_id="O3" value="3031" spread="1543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>epicatechin-glucuronide (AUC nM*hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.375" spread="2.488"/>
                    <measurement group_id="O2" value="47.18" spread="39.41"/>
                    <measurement group_id="O3" value="398.3" spread="292.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methyl-epi-sulfate (AUC nM*hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457.8" spread="211.5"/>
                    <measurement group_id="O2" value="3190" spread="496.6"/>
                    <measurement group_id="O3" value="16699" spread="7218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total parent compound and metabolites (AUC nM*hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="840.3" spread="311.1"/>
                    <measurement group_id="O2" value="4996" spread="570.0"/>
                    <measurement group_id="O3" value="22563" spread="10335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The reported P-Value was calculated</p_value_desc>
            <method>General linear mixed-effects models</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Major Safety Endpoints</title>
        <description>Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change), HR (10 bpm), creatinine (&gt;1.5 ULN), and highly conservative changes in alkaline phosphatase and liver transaminases (&gt;1.5 ULN).</description>
        <time_frame>Baseline and 24 hours</time_frame>
        <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O2">
            <title>30 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O3">
            <title>100 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Major Safety Endpoints</title>
          <description>Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change), HR (10 bpm), creatinine (&gt;1.5 ULN), and highly conservative changes in alkaline phosphatase and liver transaminases (&gt;1.5 ULN).</description>
          <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Primary hypothesis: None of the doses of (+)-epicatechin will differ with regard to change from baseline in any of the major safety endpoints; heart rate, systolic and diastolic blood pressure.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>one way ANOVA between groups</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>for change in heart rate at 24 hr post-dosing from baseline between the 3 doses</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>77.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70.3</ci_lower_limit>
            <ci_upper_limit>85.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)</title>
        <time_frame>Baseline and 24 hours</time_frame>
        <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O2">
            <title>30 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O3">
            <title>100 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)</title>
          <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
          <units>mg/dL*24hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.3" spread="158.5"/>
                    <measurement group_id="O2" value="342.6" spread="193.5"/>
                    <measurement group_id="O3" value="513.4" spread="185.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The reported P-Value was calculated</p_value_desc>
            <method>General linear mixed-effects models</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)</title>
        <time_frame>Baseline and 24 hours</time_frame>
        <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O2">
            <title>30 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O3">
            <title>100 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)</title>
          <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
          <units>uU/mL*24 hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1192" spread="488.5"/>
                    <measurement group_id="O2" value="707.2" spread="211.5"/>
                    <measurement group_id="O3" value="1334" spread="666.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The reported P-Value was calculated</p_value_desc>
            <method>General linear mixed-effects models</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)</title>
        <time_frame>Baseline and 24 hours</time_frame>
        <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O2">
            <title>30 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
          <group group_id="O3">
            <title>100 mg (+)-Epicatechin</title>
            <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)</title>
          <population>Intent to treat population (all participants who receive the medication). Last observation carried forward (LOCF) imputation method.</population>
          <units>ng/mL*24hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.74" spread="27.64"/>
                    <measurement group_id="O2" value="57.56" spread="28.56"/>
                    <measurement group_id="O3" value="64.23" spread="27.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The reported P-Value was calculated</p_value_desc>
            <method>General linear mixed-effects models</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>10 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
        <group group_id="E2">
          <title>30 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
        <group group_id="E3">
          <title>100 mg (+)-Epicatechin</title>
          <description>4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
(+)-Epicatechin: The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Headache</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent Headaches</sub_title>
                <description>Study subject reported having intermittent headaches (most likely due to lack of caffeine). Subject reported that the headaches resolved after taking the ibuprofen.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert R. Henry, MD</name_or_title>
      <organization>Va San Diego Healthcare System</organization>
      <phone>8585528585 ext 3648</phone>
      <email>rrhenry@outlook.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

